Replimune Group (NASDAQ:REPL) CEO Sushil Patel Sells 39,341 Shares

Replimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel sold 39,341 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the transaction, the chief executive officer directly owned 708,151 shares of the company’s stock, valued at approximately $9,184,718.47. This trade represents a 5.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Price Performance

Shares of REPL opened at $15.24 on Thursday. Replimune Group, Inc. has a 1-year low of $1.50 and a 1-year high of $15.68. The stock has a market cap of $1.28 billion, a PE ratio of -4.51 and a beta of 0.88. The firm has a 50-day simple moving average of $10.44 and a two-hundred day simple moving average of $7.69. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, analysts forecast that Replimune Group, Inc. will post -2.7 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on REPL. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target for the company in a research report on Friday, August 7th. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $11.00 to $17.00 in a research note on Tuesday, August 4th. Wolfe Research raised Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. JPMorgan Chase & Co. raised their target price on Replimune Group from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.86.

Hedge Funds Weigh In On Replimune Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Replimune Group by 17.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after buying an additional 6,653 shares during the period. Millennium Management LLC increased its position in shares of Replimune Group by 2.8% during the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after acquiring an additional 33,574 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after acquiring an additional 119,145 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Replimune Group by 6.9% in the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after acquiring an additional 6,616 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in Replimune Group by 149.5% in the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after purchasing an additional 18,263 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

More Replimune Group News

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: $150 million offering priced: Replimune priced a $150 million underwritten public offering, providing additional cash to support development of its oncology pipeline and RP1. The financing appears to have reassured investors about the company’s liquidity and ability to fund operations. Replimune Announces Pricing of $150 Million Underwritten Offering
• Neutral Sentiment: Insider transactions were primarily tax-related: CEO Sushil Patel, CFO Emily Hill, CAO Andrew Schwendenman and insider Konstantinos Xynos sold shares totaling approximately $1.01 million. The filings state that the sales covered tax-withholding obligations tied to vested equity awards, while each executive retained a substantial position; therefore, the transactions provide limited evidence of a change in business confidence. SEC insider transaction filing
• Negative Sentiment: Several law firms publicized a securities class action: The lawsuits cover investors who purchased Replimune securities between October 20, 2025, and April 10, 2026. The allegations claim the company misled investors about the efficacy and commercial viability of RP1 and failed to disclose unresolved FDA study-design concerns. CEO Sushil Patel and CFO Emily Hill are named as individual defendants, and the lead-plaintiff deadline is October 5, 2026. The notices increase legal and reputational uncertainty, although the allegations have not been proven. REPL Class Action Reminder Levi and Korsinsky class action notice

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.